Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
The deal ends Poxel’s long wait for a partner capable of running a late-phase diabetes program and starts Roivant’s expansion into metabolic diseases.
Syndax is set to put its cocktail through a phase 1b solid tumor trial ahead of midphase trials to demonstrate its safety and efficacy.
The amended agreement gives Editas until the end of September to exercise its option on the first of five ocular indications covered by the contract.
The aim is to apply Synpromics’ synthetic promoter expertise to the development of gene therapies against diseases affecting the blood.
John Hohneker will join Anokion Therapeutics as president and CEO from Forma Therapeutics, where he served as R&D chief.
The MDC identified efforts to make informatics tools, preclinical models, data and samples available to startups as the best uses of its resources.
The company's Owkin Socrates platform applies transfer and federated learning to clinical research.
The pact sets Merck up to work with researchers at CRUK’s unit at the ICR on three preclinical oncology projects.
The agreement tasks Adimab with turning its yeast-based antibody discovery platform against multiple targets picked out by Boehringer.